peptide therapeutics
2 articles tagged with ‘peptide therapeutics’
Ved Srivastava on Peptide Science from Early Days to AI Era
Dr. Ved Srivastava, Chief Scientific Officer at Perpetual Medicines, shares his career in peptide therapeutics. He contributed to drugs like Byetta (exenatide), Bydureon, and Symlin (pramlintide). In a discussion, he covers the field's evolution and 2026 trends including macrocyclic peptides and AI design.

PEGylation Shields Peptides from Immune Recognition
PEGylation covers peptide surfaces with a flexible polyethylene glycol layer that blocks immune detection. This process hides epitopes from antibodies and receptors, prevents breakdown into immunogenic fragments, and boosts hydrodynamic size to evade antigen presentation. As a result, it cuts risks of anti-drug antibodies, hypersensitivity, and clinical failures seen in early peptide drugs.